Health Equity And Access | Varsity Tutors

SECTION 1

Historical Context & Motivation

The concept of health equity did not arise in a vacuum; rather, it emerged from centuries of documented disparities in disease burden, access to care, and health outcomes across racial, socioeconomic, and geographic lines. In the United States, the intersection of slavery, segregation, and systematic exclusion from medical institutions created deeply embedded structural inequities that persist to this day. Early public health efforts in the 19th century, while groundbreaking in addressing infectious disease, often reinforced existing power hierarchies and ignored the needs of marginalized communities. The formal recognition that social determinants of health drive outcomes more than clinical interventions alone represented a paradigm shift in how healthcare professionals—including pharmacists—conceptualize their role in society.

1965

Medicare & Medicaid Enacted

The Social Security Amendments established Medicare and Medicaid, dramatically expanding insurance coverage for elderly and low-income populations and beginning the federal commitment to reducing access barriers.

1985

Heckler Report on Minority Health

The landmark HHS Secretary's Task Force report documented excess deaths among Black and minority populations, catalyzing the creation of the Office of Minority Health and framing health disparities as a national priority.

2003

IOM's 'Unequal Treatment' Published

The Institute of Medicine published 'Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care,' providing irrefutable evidence that disparities persist even after controlling for insurance status and clinical factors.

2010

Affordable Care Act Signed

The ACA expanded Medicaid eligibility, prohibited insurance discrimination based on pre-existing conditions, and introduced provisions targeting health disparities reduction—fundamentally reshaping the access landscape.

2020–2021

COVID-19 Exposes Systemic Inequities

The pandemic disproportionately impacted communities of color and low-income populations, revealing gaps in testing access, vaccine distribution, and pharmacy services in underserved areas, accelerating national discourse on equity.

These historical milestones demonstrate that health equity is not simply an aspirational ideal but an evolving policy and practice framework. For pharmacists preparing for the NAPLEX and clinical practice, the critical question remains: how can pharmaceutical professionals identify, measure, and actively mitigate disparities in medication access, adherence, and outcomes within the communities they serve? This lesson addresses that question by examining the core principles, frameworks, and practical strategies that underpin equitable pharmacy practice.

SECTION 2

Core Principles & Definitions

Before examining specific strategies, it is essential to distinguish between terms that are frequently—and incorrectly—used interchangeably. Health equality refers to providing every individual with the same resources and opportunities, while health equity requires distributing resources according to need so that every person can attain their highest possible level of health. Health equity explicitly acknowledges that different populations start from different positions due to historical and structural disadvantage. Health disparities are the measurable differences in health outcomes and their determinants between population segments, while health access encompasses the timely use of personal health services to achieve the best health outcomes, including factors such as insurance coverage, geographic proximity to providers, affordability of medications, and cultural competency of care.

Social Determinants of Health (SDOH)

The conditions in which people are born, grow, live, work, and age—including economic stability, education, neighborhood environment, food access, and social context—that shape 80% of health outcomes.

Structural Competency

The trained ability to recognize how institutions, policies, and social structures—rather than individual behaviors alone—produce health inequities, and to incorporate that understanding into clinical decision-making.

Medication Access & Affordability

The degree to which patients can obtain prescribed medications without undue financial burden—influenced by insurance formularies, out-of-pocket costs, pharmacy deserts, and patient assistance programs.

Cultural Humility

A lifelong process of self-reflection and self-critique whereby pharmacists seek to understand and address power imbalances in the patient–provider dynamic, moving beyond static cultural competence to ongoing learning.

Health Literacy

The capacity of individuals to obtain, process, and understand basic health information needed to make appropriate decisions—directly affecting medication adherence, self-management, and communication with providers.

✦ KEY TAKEAWAY

Think of health equity like prescribing corrective lenses: equality would mean giving everyone the same pair of glasses, but equity means performing a refraction for each patient and dispensing individualized prescriptions. The pharmacist's role is to 'refract' each patient's social, economic, and cultural circumstances and tailor interventions—whether that is selecting a lower-cost therapeutic alternative, providing counseling in a patient's preferred language, or connecting them with a patient assistance program—so that every patient can see clearly on their path to wellness.

SECTION 3

Visualizing the Determinants of Health Equity

This nested ecological model illustrates how patient health outcomes sit at the center of concentric layers—individual factors (health literacy, adherence behaviors), community and environmental factors (pharmacy deserts, food access), and policy and structural factors (insurance mandates, systemic racism). Pharmacy professionals interact with all three layers when addressing health equity.

The diagram above represents an ecological model adapted for pharmacy practice. At the center lies the individual patient and their ultimate health outcome. Surrounding this core are three concentric rings of influence. The innermost ring captures individual-level factors such as health literacy, language preference, and medication adherence behaviors. The middle ring represents community-level factors including the presence or absence of pharmacies, transportation infrastructure, and neighborhood safety. The outermost ring encompasses structural and policy factors such as insurance coverage mandates, formulary design, drug pricing legislation, and institutional racism. Pharmacists who understand this multilevel framework can identify leverage points at each layer—from individual counseling to community-based screening events to advocacy for policy change.

SECTION 4

Mechanisms & Frameworks for Measuring Disparities

While health equity may seem primarily qualitative, there are well-established quantitative methods for measuring and tracking health disparities. Pharmacists should be familiar with several key metrics that appear in public health reporting and quality improvement programs. Understanding these metrics enables pharmacists to evaluate whether their interventions are actually reducing inequities or merely improving aggregate outcomes while leaving gaps intact.

Disparity Metrics Used in Pharmacy Quality Programs

ABSOLUTE DISPARITY

Absolute Disparity = Rate(disadvantaged group) − Rate(reference group)

Measures the arithmetic difference in a health outcome (e.g., medication adherence rate) between two population groups. A positive value indicates the disadvantaged group has a higher rate of the adverse outcome.

RELATIVE DISPARITY

Relative Disparity = (Rate(disadvantaged) − Rate(reference)) ÷ Rate(reference) × 100%

Expresses the disparity as a percentage of the reference group's rate. Relative measures are essential because a small absolute gap can represent a large relative burden if the reference rate is low.

PROPORTION OF DAYS COVERED (PDC)

PDC = (Total days with medication on hand ÷ Number of days in measurement period) × 100%

PDC ≥ 80% is the CMS quality benchmark for adherence in chronic disease medications (statins, ACE inhibitors/ARBs, oral diabetes agents). Stratifying PDC by race, ethnicity, income, or ZIP code reveals disparity patterns relevant to pharmacy quality measures.

CMS Star Ratings, which directly affect Medicare Advantage plan reimbursement, now include health equity measures. Beginning in 2024, CMS introduced the Health Equity Index (HEI) as a reward factor in the Star Rating system, incentivizing plans that perform well among enrollees receiving low-income subsidies. Pharmacists working in managed care, health-system pharmacy, or community pharmacy settings should understand that stratified quality measurement—breaking down aggregate PDC or other adherence metrics by demographic subgroups—is the foundational step in identifying where disparities exist and targeting interventions accordingly.

📋 NAPLEX Relevance

The NAPLEX competency statements explicitly address the pharmacist's responsibility to promote health equity. Expect questions on identifying social determinants, recommending culturally appropriate interventions, selecting cost-effective therapeutic alternatives, and understanding how formulary design impacts vulnerable populations.

SECTION 5

Barriers to Medication Access — A Detailed Breakdown

Barriers to medication access are multidimensional and often intersecting. A patient who lives in a pharmacy desert—a geographic area where residents must travel significant distances to reach a pharmacy—may also face limited public transportation, lower income, and reduced health literacy. These compounding barriers create cascading effects on adherence, disease management, and emergency utilization rates. Understanding these barriers is essential for pharmacists seeking to intervene effectively.

This cascade model traces how upstream structural factors flow through insurance, affordability, geographic, literacy, and cultural barriers to produce medication non-adherence and ultimately adverse health outcomes. Pharmacist interventions can be targeted at multiple points along this cascade.

Common barriers to medication access and corresponding pharmacist-driven interventions

Barrier Category	Specific Examples	Pharmacist Intervention Strategies
Financial / Affordability	High copays, lack of insurance, expensive specialty drugs, step therapy requirements	Therapeutic substitution to generics, patient assistance programs (PAPs), 340B referrals, manufacturer coupons, splitting tablets when appropriate
Geographic / Transportation	Rural pharmacy closures, urban pharmacy deserts, limited public transit	Mail-order pharmacy enrollment, 90-day supply dispensing, telepharmacy, mobile health clinics, medication synchronization (med sync)
Health Literacy / Language	Complex regimens, English-only labels, low numeracy, limited English proficiency (LEP)	Teach-back method, multilingual labeling, pictogram-based instructions, plain language counseling, interpreter services
Cultural / Trust	Historical medical mistreatment, implicit provider bias, stigma around mental health or HIV	Cultural humility training, diversifying pharmacy workforce, community health worker partnerships, shared decision-making, stigma-free language
Systemic / Institutional	Restrictive formularies, prior authorization delays, lack of Medicaid expansion in some states	Advocacy for formulary reform, prior authorization assistance, P&T committee participation, supporting Medicaid expansion policies

SECTION 6

Worked Example — Identifying and Addressing a Disparity

Consider the following clinical scenario that integrates disparity identification, metric calculation, and intervention design—the type of integrated thinking the NAPLEX increasingly tests.

Diabetes Medication Adherence Disparity in a Community Pharmacy

Step 1 — Review the ScenarioA community pharmacy in an urban area serves a diverse population. The pharmacy manager reviews PDC data for oral diabetes medications (Part D measure) and finds the following: White patients have an average PDC of 85%, while Hispanic/Latino patients have an average PDC of 68%. The pharmacy serves 200 White patients and 150 Hispanic/Latino patients on oral diabetes medications.

Step 2 — Calculate Absolute DisparityAbsolute Disparity = Rate(disadvantaged) − Rate(reference) = 68% − 85% = −17 percentage points. The negative value (when framed as adherence) indicates the Hispanic/Latino group is 17 percentage points below the reference group. Alternatively, if we frame it as non-adherence: 32% − 15% = +17 percentage points of excess non-adherence.

Absolute disparity = 17 percentage points in non-adherence

Step 3 — Calculate Relative DisparityRelative Disparity = (32% − 15%) ÷ 15% × 100% = 17 ÷ 15 × 100% ≈ 113%. The Hispanic/Latino population has a non-adherence rate approximately 113% higher than the White reference population—more than double.

Relative disparity ≈ 113% excess non-adherence

Step 4 — Identify Root Causes Using SDOH FrameworkThe pharmacist interviews patients and staff and identifies three key contributing factors: (1) approximately 40% of Hispanic/Latino patients are Spanish-dominant speakers and counseling is conducted exclusively in English; (2) many patients report inability to afford $35 copays on generic metformin combinations; and (3) transportation to the pharmacy is a cited barrier, with no bus route nearby.

Step 5 — Design Targeted InterventionsBased on the root cause analysis, the pharmacist implements: (a) bilingual counseling sessions and Spanish-language medication labels using translated auxiliary labels; (b) enrollment of eligible patients in manufacturer patient assistance programs and evaluation of therapeutic alternatives with lower copays; (c) a medication synchronization (med sync) program allowing 90-day fills to reduce trip frequency; and (d) a follow-up phone call protocol at 30, 60, and 90 days to monitor adherence.

Multilevel intervention: language-concordant counseling + financial assistance + med sync + follow-up

Step 6 — Measure Outcomes and ReassessAfter 6 months, the pharmacy re-stratifies PDC data. Hispanic/Latino PDC has improved to 79%, narrowing the absolute disparity from 17 to 6 percentage points. While not yet eliminated, this improvement demonstrates the value of targeted, equity-focused interventions and justifies continued resource allocation.

Disparity reduced from 17 to 6 percentage points (65% reduction in absolute disparity)

SECTION 7

Pharmacist Strategies — Strengths & Limitations

Pharmacists are uniquely positioned among healthcare professionals to address health equity because of their accessibility, frequency of patient encounters, and expertise in medication management. Community pharmacies, in particular, are often the most accessible healthcare touchpoints in underserved areas. However, each intervention strategy carries both strengths and limitations that must be understood in context.

Pharmacist-driven health equity strategies with corresponding strengths and limitations

Strategy	Strengths	Limitations
Patient Assistance Programs (PAPs)	Directly reduce financial barriers; many manufacturer programs cover brand medications at no cost; can be combined with copay cards	Complex enrollment processes; eligibility criteria vary; often unavailable for generics; unsustainable long-term without systemic pricing reform
340B Drug Pricing Program	Allows covered entities to purchase medications at significant discounts; savings can fund expanded services for vulnerable populations	Limited to eligible entities (FQHCs, DSH hospitals); savings not always passed directly to patients; program integrity concerns and legislative uncertainty
Medication Therapy Management (MTM)	Comprehensive medication reviews identify adherence gaps, drug interactions, and cost-saving opportunities; required for Part D plans	Narrow targeting criteria often miss patients who most need services; reimbursement may not cover true cost; language barriers reduce effectiveness without interpreter support
Telepharmacy / Telehealth	Extends pharmacist reach to rural and underserved areas; reduces transportation barriers; flexible scheduling improves access for working patients	Digital divide—broadband access inequity; may reduce relationship quality; regulatory limitations vary by state; technology literacy barriers for elderly patients
Community Health Worker Partnerships	Culturally concordant outreach; trusted community presence; can bridge pharmacy and patient home environments; effective for chronic disease management	Funding often grant-dependent and unsustainable; scope of practice limitations; need for pharmacist oversight and integration into workflow

✦ KEY TAKEAWAY

No single intervention addresses all barriers simultaneously—just as a multi-drug regimen targets different pathways in a disease process, an equity-focused pharmacy practice must deploy a combination of financial, linguistic, geographic, and cultural strategies. The pharmacist serves as the 'polypharmacy manager' of equity interventions, selecting, monitoring, and adjusting the combination to optimize outcomes for each patient population.

SECTION 8

Policy Landscape & Future Directions in Pharmacy Equity

The regulatory and policy environment surrounding health equity in pharmacy is evolving rapidly. Pharmacists must understand both current policy frameworks and emerging trends that will reshape practice in the coming years. The shift from volume-based to value-based reimbursement inherently elevates the importance of equity, because quality measures stratified by demographics expose disparities that aggregate metrics conceal. This section compares the current state of pharmacy equity policy with the emerging advanced framework.

Comparison of current and emerging policy frameworks for pharmacy-based health equity

Dimension	Current Framework	Emerging / Advanced Framework
Quality Measurement	Aggregate Star Rating measures (PDC, CMR completion); limited demographic stratification	Health Equity Index (HEI) as reward factor; mandatory SDOH data collection; race/ethnicity-stratified PDC reporting
Pharmacist Scope	Dispensing-centered with optional MTM; limited provider status recognition	Expanded scope via PREP Act extensions, state-level provider status, test-and-treat authority, and immunization equity mandates
Drug Pricing	340B for covered entities; PAPs as stopgaps; high out-of-pocket burden	Inflation Reduction Act caps insulin at $35/month for Medicare; CMS drug price negotiation; state-level PBM transparency laws
Data Infrastructure	Incomplete race/ethnicity data in pharmacy systems; ZIP code as imperfect proxy for SDOH	Interoperable EHR-pharmacy data; Z-codes for SDOH documentation; area deprivation index integration into clinical decision support
Education & Training	Cultural competency as elective or minimal curricular requirement in PharmD programs	ACPE accreditation standards requiring structural competency, implicit bias training, and health equity longitudinal threads throughout the curriculum

Looking forward, pharmacists will increasingly be expected to function not only as medication experts but as population health managers who leverage data to identify at-risk subgroups, design targeted interventions, and advocate for policy changes that address root causes of inequity. The integration of SDOH Z-codes (ICD-10-CM codes Z55–Z65) into pharmacy documentation systems will enable more precise measurement of social risk factors and their impact on medication outcomes, creating a feedback loop between clinical practice and equity-focused quality improvement.

SECTION 9

Practice Problems

PROBLEM 1 — CONCEPTUAL

A pharmacy student argues that 'health equity' and 'health equality' are synonymous because both aim to improve health outcomes. Explain, using a clinical pharmacy example, why this conflation is incorrect and how the distinction matters for pharmacy practice.

PROBLEM 2 — BASIC CALCULATION

In a Medicare Part D plan, the statin PDC for White enrollees is 82% and for Black enrollees is 71%. Calculate both the absolute and relative disparity in non-adherence (defined as PDC < 80%).

PROBLEM 3 — INTERMEDIATE

A pharmacist at a Federally Qualified Health Center (FQHC) notices that patients in ZIP codes with high Area Deprivation Index (ADI) scores have a 40% prescription abandonment rate for GLP-1 receptor agonists, compared to 12% in lower-ADI areas. The FQHC participates in the 340B program. Describe a multi-component intervention plan the pharmacist could implement, identifying which specific barrier each component addresses.

PROBLEM 4 — APPLIED

During the COVID-19 pandemic, a state health department partners with community pharmacies to administer vaccines. Data reveal that vaccination rates in predominantly Black and Hispanic neighborhoods are 35% lower than in White neighborhoods despite equitable geographic distribution of pharmacy vaccination sites. As a pharmacist consultant, what factors beyond site placement might explain this disparity, and what evidence-based strategies would you recommend?

PROBLEM 5 — CRITICAL THINKING

CMS has introduced the Health Equity Index (HEI) as a reward factor in Medicare Star Ratings. Some critics argue that rewarding plans for equity performance could paradoxically incentivize plans to avoid enrolling populations with complex social needs, while proponents argue it creates accountability. Analyze both perspectives and propose a pharmacy-specific safeguard that could mitigate the risk of adverse selection while preserving equity incentives.

SUMMARY

Lesson Summary — Health Equity and Access in Pharmacy Practice

Health equity is not merely an aspirational principle but an operational framework requiring pharmacists to recognize and address social determinants of health—including economic instability, geographic barriers, health literacy gaps, and cultural mistrust—that drive disparities in medication access, adherence, and outcomes. Historical milestones from Medicare's creation through the COVID-19 pandemic demonstrate that structural inequities are deeply rooted and require sustained, multilevel intervention. Pharmacists can quantify disparities using absolute and relative disparity metrics and stratified PDC data to identify where gaps exist.

Key intervention strategies include patient assistance programs, 340B drug pricing, medication therapy management, telepharmacy, cultural humility practices, and community health worker partnerships. The emerging policy landscape—including the CMS Health Equity Index, the Inflation Reduction Act, and ACPE accreditation reforms—signals that health equity competency is no longer optional but foundational for pharmacists. For NAPLEX preparation, focus on the ability to identify barriers, calculate disparity metrics, select appropriate interventions, and critically evaluate policy mechanisms that promote or hinder equitable medication access.